Brief: Geneuro to present 12 Month data on anti-Neurodegeneration effects of Gnbac1 From Change-MS Phase 2B Study
10/10/2018 06:37
Oct 10 (Reuters) - Geneuro SA GNRO.PA :
* GENEURO TO PRESENT 12 MONTH DATA ON ANTI-NEURODEGENERATION
EFFECTS OF GNBAC1 FROM CHANGE-MS PHASE 2B STUDY IN MULTIPLE
SCLEROSIS AT ECTRIMS 2018
((sudip.kargupta@thomsonreuters.com;))
Recent news on Geneuro SA
See all newsBrief: Geneuro SA Postpones Publication Of Half-Yearly Financial Report
Brief: Geneuro SA Announces Extension Of Its Definitive Debt-Restructuring Moratorium
Brief: Geneuro SA Announces The Opening Of Receivership Proceedings For Its French Subsidiary Geneuro Innovation Sas
Brief: Geneuro Confirms Top-Line Results In Its Post-Covid Trial By End-June
Brief: Geneuro announces EUR 5 Mln private placement